ArticleFrontiers in endocrinology2025
Clinical and morphological predictors of metastasis in papillary thyroid microcarcinoma.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Papillary thyroid microcarcinomas (PTMCs), defined as papillary thyroid carcinomas measuring ≤1 cm, are frequently diagnosed incidentally and are generally associated with favorable outcomes. However, a significant subset of patients develops regional lymph node metastases. This study aimed to identify clinical and morphological features associated with metastatic spread in PTMCs. Methods: A total of 100 cases were retrospectively analyzed, including 50 with confirmed lymph node metastases and 50 without. A detailed histological assessment included evaluation of tumor subtype, nuclear features, presence of psammoma bodies, tumor "buds," fibrosis, and other parameters. Clinical variables such as age, sex, body mass index, and presence of the BRAF V600E mutation were also considered. Results: Logistic regression revealed that younger age, classical histological subtype, tumor "budding," and presence of psammoma bodies were independently associated with an increased risk of regional metastases, while concomitant multinodular hyperplasia was negatively associated. Discussion: The combination of these features may enhance risk stratification and guide the clinical management of PTMC patients, including decisions on surgical extent and follow-up strategies. Our findings support the relevance of comprehensive histological and clinical evaluation in predicting the metastatic potential of PTMCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.